Earnings summaries and quarterly performance for Sight Sciences.
Executive leadership at Sight Sciences.
PB
Paul Badawi
Detailed
Chief Executive Officer
CEO
AB
Alison Bauerlein
Detailed
Chief Operating Officer
BT
Brenton Taylor
Detailed
Executive Vice President, Operations
DB
David Badawi, M.D.
Detailed
Chief Technology Officer
JR
James Rodberg
Detailed
Chief Financial Officer and Treasurer
JH
Jeremy Hayden
Detailed
Chief Legal Officer
MR
Manohar Raheja
Detailed
Executive Vice President, Research & Development
Board of directors at Sight Sciences.
Research analysts who have asked questions during Sight Sciences earnings calls.
Thomas Stephan
Stifel
6 questions for SGHT
Also covers: ALC, GKOS, GMED +2 more
Frank Takkinen
Lake Street Capital Markets
5 questions for SGHT
Also covers: ANGO, AORT, AXGN +18 more
DS
David Saxon
Needham & Company
4 questions for SGHT
Also covers: ALC, ALGN, ATEC +11 more
DA
Danielle Antalffy
UBS Group AG
3 questions for SGHT
Also covers: ABT, ATRC, BAX +15 more
Adam Maeder
Piper Sandler Companies
2 questions for SGHT
Also covers: ABT, AXNX, EW +15 more
DA
Danielle Antalffy
UBS
2 questions for SGHT
Also covers: ATRC, BAX, BBNX +13 more
Joanne Wuensch
Citigroup Inc.
2 questions for SGHT
Also covers: ABT, BAX, BDX +19 more
MK
Macauley Kilbane
William Blair & Company
2 questions for SGHT
Also covers: CBLL, CVRX, GKOS +4 more
PD
Phillip Dantoin
Piper Sandler
2 questions for SGHT
Also covers: ATEC, CNMD, FNA +2 more
SL
Steve Lichtman
William Blair
2 questions for SGHT
Also covers: GKOS
Justin Lang
Morgan Stanley
1 question for SGHT
Also covers: CW, GOGO, IRDM +5 more
KW
Kyle Winborne
Piper Sandler Companies
1 question for SGHT
Also covers: STXS, TCMD
MA
Michael Arens
William Blair
1 question for SGHT
Nelson Cox
Lake Street Capital Markets
1 question for SGHT
Also covers: AORT, AQST, CVRX +7 more
Recent press releases and 8-K filings for SGHT.
Sight Sciences Announces Q4 2025 Results and Initiates 2026 Guidance
SGHT
Earnings
Guidance Update
New Projects/Investments
- Sight Sciences reported Q4 2025 total revenue of $20.4 million, a 7% increase year-over-year, resulting in a net loss of $4.2 million or $0.08 per share, and ended the quarter with $92 million in cash.
- For full-year 2026, the company initiated revenue guidance of $82 million to $88 million (reflecting 6%-14% growth) and adjusted operating expense guidance of $93 million to $96 million (representing a 6%-9% increase).
- Interventional Dry Eye (IDE) revenue was $0.7 million in Q4 2025, reflecting positive traction after CGS, Novitas Solutions, and First Coast Service Options established pricing for the TearCare CPT code 0563T.
- Interventional Glaucoma (IG) revenue grew 5% to $19.7 million in Q4 2025, and the company is making targeted investments to activate the standalone glaucoma market.
8 days ago
Sight Sciences Announces Q4 2025 Results and Initiates 2026 Guidance
SGHT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Sight Sciences reported Q4 2025 total revenue of $20.4 million, a 7% increase year-over-year, with interventional glaucoma revenue at $19.7 million (up 5%) and interventional dry eye revenue at $0.7 million (up from $0.3 million).
- The company achieved a gross margin of 87% and significantly reduced total operating expenses by 25% to $21.5 million in Q4 2025, resulting in a net loss of $4.2 million or $0.08 per share.
- For full year 2026, Sight Sciences initiated revenue guidance of $82 million to $88 million, reflecting 6%-14% growth, with interventional glaucoma projected at $77 million to $81 million and interventional dry eye at $5 million to $7 million.
- A key milestone in Q4 2025 was the establishment of pricing for CPT code 0563T for its TearCare procedure by TuMax, Novitas Solutions, and First Coast Service Options, marking a turning point for the reimbursed interventional dry eye market.
- The company plans to make additional investments in its interventional dry eye commercial organization and market access, while also focusing on developing the standalone glaucoma market with OMNI.
8 days ago
Sight Sciences Reports Q4 2025 Results and Initiates 2026 Guidance
SGHT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Sight Sciences reported Q4 2025 total revenue of $20.4 million, a 7% increase year-over-year, driven by $19.7 million in interventional glaucoma revenue (up 5%) and $0.7 million in interventional dry eye revenue.
- The company achieved a significant reimbursement milestone in Q4 2025 with the establishment of pricing for CPT code 0563T for its TearCare procedure by TuMax, Novitas Solutions, and First Coast Service Options.
- For full year 2026, Sight Sciences initiated revenue guidance of $82 million to $88 million, reflecting 6%-14% growth, and adjusted operating expense guidance of $93 million to $96 million.
- Net loss for Q4 2025 was $4.2 million, or $0.08 per share, with $92 million in cash and cash equivalents at quarter-end, reflecting continued operational discipline and a 25% decrease in total operating expenses year-over-year.
8 days ago
Sight Sciences Reports Q4 and Full Year 2025 Financial Results and Initiates 2026 Guidance
SGHT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Sight Sciences reported fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2024.
- The company achieved a full year 2025 operating expense reduction of 13% compared to full year 2024, and reduced cash usage to $0.4 million in the fourth quarter 2025.
- Net loss for full year 2025 was $38.4 million, or a loss of $0.74 per share, an improvement from a net loss of $51.5 million, or $1.03 per share, for full year 2024.
- Cash and cash equivalents totaled $92.0 million as of December 31, 2025.
- For full year 2026, Sight Sciences expects revenue to range from $82 million to $88 million, representing growth of 6% to 14% compared to full year 2025, and adjusted operating expenses to range from $93 million to $96 million.
8 days ago
Sight Sciences Announces Preliminary Q4 and Full Year 2025 Financial Highlights
SGHT
Earnings
Guidance Update
- Sight Sciences, Inc. reported preliminary unaudited fourth quarter 2025 total revenue is expected to be between $20.3 million and $20.4 million, an increase of 7% at the estimated midpoint compared to the prior year period.
- For the full year 2025, total revenue is expected to be in the range of $77.3 million to $77.4 million, representing a 3% decrease at the estimated midpoint compared to the prior year.
- Dry Eye revenues for Q4 2025 are expected to be approximately $0.7 million, an increase of approximately 130% compared to the prior year period.
- The company's cash and cash equivalents as of December 31, 2025, were approximately $92 million, with $0.4 million cash used in the fourth quarter and $28 million used during the full year.
Jan 13, 2026, 12:09 PM
Sight Sciences Announces Preliminary Q4 and Full Year 2025 Financial Highlights
SGHT
Earnings
Guidance Update
- Fourth quarter 2025 total revenue is expected to be in the range of $20.3 million to $20.4 million, an increase of 7% at the estimated midpoint compared to the prior year period.
- Full year 2025 total revenue is anticipated to be between $77.3 million and $77.4 million, representing a 3% decrease at the estimated midpoint compared to the prior year.
- As of December 31, 2025, cash and cash equivalents were approximately $92 million, with $0.4 million cash used in the fourth quarter and $28 million used during the full year.
- Management expressed confidence in the company's growth outlook, operational discipline, and path toward cash flow breakeven without requiring additional equity capital.
Jan 13, 2026, 12:05 PM
Sight Sciences Discusses Q3 Highlights, TearCare Commercialization, and Glaucoma Performance
SGHT
Guidance Update
Revenue Acceleration/Inflection
Management Change
- Sight Sciences highlighted recent TearCare market access wins with First Coast and Novitas, with commercialization underway in these covered areas. The company expects $500,000-$1,000,000 in dry eye sales in Q4 2025 from these efforts, with sales ramping in 2026, targeting a large market of 6-8 million moderate to severe MGD patients.
- The company is performing well in its surgical glaucoma business, gaining sequential share from Glaukos for the second straight quarter. Q4 2025 glaucoma guidance is for flattish to high single-digit growth year over year.
- Sight Sciences reported over $90 million in cash and is confident in its pathway to break-even without needing additional equity capital. The company also underwent restructuring to enhance focus on its two growth opportunities (MIGS and evaporative dry eye disease) and operate more leanly.
- Recent management changes include the promotion of Ali to Chief Operating Officer and Jim to Chief Financial Officer.
Nov 11, 2025, 4:20 PM
Sight Sciences Reports Q3 2025 Results, Raises Full-Year Revenue Guidance, and Achieves Key Reimbursement Milestone
SGHT
Earnings
Guidance Update
Management Change
- Sight Sciences reported Q3 2025 total revenue of $19.9 million, a 1% decrease year-over-year, and a net loss of $8.2 million, or $0.16 per share.
- The company raised its full-year 2025 revenue guidance to $76 million-$78 million (from $72 million-$76 million) and reduced its adjusted operating expense guidance to $90 million-$92 million.
- Significant progress was made in dry eye reimbursement, with two MACs (Novitas and First Coast) establishing jurisdiction-wide pricing for TearCare CPT code 0563T at approximately $1,142 per procedure, retroactive to January 1, 2025.
- The surgical glaucoma segment's Q3 2025 revenue increased by 6% to $19.7 million compared to the prior year, driven by growth in ordering accounts and average selling prices.
- Jim Murphy was appointed CFO and Ali Bauerlein was appointed COO.
Nov 6, 2025, 9:30 PM
Sight Sciences Reports Q3 2025 Results, Raises Revenue Guidance, and Announces Executive Appointments
SGHT
Earnings
Guidance Update
Management Change
- Sight Sciences reported Q3 2025 total revenue of $19.9 million, a 1% decrease compared to the same period in the prior year, and a net loss of $8.2 million, or a loss of $0.16 per share.
- The company raised its full year 2025 revenue guidance to $76.0 million to $78.0 million and reduced its adjusted operating expense guidance to $90 million to $92 million.
- Alison Bauerlein was promoted to Chief Operating Officer, and James Rodberg was promoted to Chief Financial Officer and Treasurer, both effective November 5, 2025.
- Erica Rogers and Brenda Becker stepped down from the Board of Directors, effective November 4, 2025, leading to a reduction in the Board's size from nine to seven members.
Nov 6, 2025, 9:11 PM
Sight Sciences reports Q3 2025 results and raises full year revenue guidance
SGHT
Earnings
Guidance Update
Management Change
- Sight Sciences reported total revenue of $19.9 million for the third quarter ended September 30, 2025, representing a 1% decrease compared to the prior year, with Surgical Glaucoma revenue increasing 6% and Dry Eye revenue decreasing 88%.
- Total operating expenses were $25.1 million in the third quarter of 2025, an 11% decrease year-over-year, leading to a net loss of $8.2 million, or $0.16 per share.
- The company raised its full year 2025 revenue guidance to $76.0 million to $78.0 million and reduced its adjusted operating expenses guidance to $90 million to $92 million.
- Alison Bauerlein was appointed Chief Operating Officer and James Rodberg was appointed Chief Financial Officer, effective November 5, 2025.
Nov 6, 2025, 9:05 PM
Quarterly earnings call transcripts for Sight Sciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more